VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 29 filers reported holding VERONA PHARMA PLC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,147,000 | +1719.5% | 210,100 | +645.0% | 0.00% | – |
| Q2 2022 | $118,000 | -32.2% | 28,200 | +13.7% | 0.00% | – |
| Q4 2020 | $174,000 | +74.0% | 24,800 | +15.8% | 0.00% | – |
| Q2 2020 | $100,000 | +38.9% | 21,410 | +71.3% | 0.00% | – |
| Q4 2019 | $72,000 | +35.8% | 12,500 | +21.4% | 0.00% | – |
| Q2 2019 | $53,000 | -30.3% | 10,300 | -12.0% | 0.00% | – |
| Q1 2019 | $76,000 | – | 11,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,332,485 | $34,817,833 | 22.99% |
| Abingworth LLP | 2,457,500 | $64,214,475 | 20.92% |
| Fairmount Funds Management LLC | 2,875,526 | $75,137,494 | 11.92% |
| Octagon Capital Advisors LP | 2,468,000 | $64,488,840 | 10.04% |
| NEA Management Company, LLC | 5,584,753 | $145,929,596 | 8.20% |
| Knoll Capital Management, LLC | 95,391 | $2,492,567 | 5.62% |
| Frazier Life Sciences Management, L.P. | 2,815,720 | $73,574,764 | 4.57% |
| Resolute Capital Asset Partners LLC | 185,992 | $4,860 | 4.34% |
| Caligan Partners LP | 183,064 | $4,783,462 | 3.98% |
| Samsara BioCapital, LLC | 695,001 | $18,160,376 | 3.91% |